Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04967664 · ClinicalTrials.gov registry record · Phase 3
Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery
A Phase 3 study of Post Surgical Neuropathic Pain, sponsored by Averitas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 409
- Enrollment target
- 20
- Study locations
NCT04967664: Completed Phase 3 study of Post Surgical Neuropathic Pain, sponsored by Averitas Pharma.
NCT04967664 is a Phase 3 study of Post Surgical Neuropathic Pain that has completed, run by Averitas Pharma. The registered enrollment target is 409 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04967664, a Phase 3 study of Post Surgical Neuropathic Pain, has completed, sponsored by Averitas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 409 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).
Primary Outcome
For the US. The 24-hr average pain intensity will be assessed and reported in the electronic diary (e-diary) once daily in the evening, using an 11-point numeric pain rating scale (NPRS, from 0 = no pain to 10 = pain as bad as you can imagine).
Conditions Studied
Interventions
- DRUG Qutenza (capsaicin) 8% topical system
- DRUG capsaicin 0.04% topical system
Study Locations (20)
Florida
- South Lake Pain Institute - Clermont
- University Clinical Research - DeLand Clinical Research Unit - DeLand
- Florida Research Center, Inc. - Miami
- Clinical Research of West Florida - Tampa
Kansas
- Neuroscience Research Center, LLC - Overland Park
- Kansas City Bone & Joint Clinic, P.A. - Overland Park
North Carolina
- Accellacare - Wilmington
- The Center for Clinical Research - Winston-Salem
Arizona
- Tucson Orthopaedic Institute - Tucson
California
- ILD Research Center - Vista
District of Columbia
- International Spine, Pain, and Performance Center - Washington D.C.
Georgia
- Drug Studies America - Marietta
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2025-08-28 |
| Phase | Phase 3 |
What the finished NCT04967664 record still lists
NCT04967664 is an interventional study that assigns participants to a tested intervention. The registered 409 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Post Surgical Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Qutenza (capsaicin) 8% topical system is the first listed.
NCT04967664 names 20 study sites across 15 states, led by Florida, Kansas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04967664 about?
NCT04967664 is a clinical study titled "Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery". This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in sub...
What is the current status of trial NCT04967664?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 409 participants. The study started on 2021-07-13. Estimated completion is 2025-08-28.
What conditions does trial NCT04967664 study?
This clinical trial studies the following conditions: Post Surgical Neuropathic Pain.
What interventions are being tested in trial NCT04967664?
The interventions under investigation include: Qutenza (capsaicin) 8% topical system (DRUG), capsaicin 0.04% topical system (DRUG).
Who is sponsoring clinical trial NCT04967664?
This trial is sponsored by Averitas Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04967664 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04967664's enrollment target sits among peer trials
409 911th of 2000 higher than 1,090 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717334 · 409 participants
A Study of Lung Cancer Screening in People With Unexplained Weight Loss
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI